Genmab A/S ( GMAB ) NASDAQ Global Select

Cena: 23.86 ( 4.31% )

Aktualizacja 07-24 16:10
NASDAQ Global Select
Branża: Biotechnology

Notowania:


Opis firmy:

Genmab A/S rozwija terapeutyki przeciwciał w leczeniu raka i innych chorób przede wszystkim w Danii. Firma sprzedaje Darzalex, ludzkie przeciwciało monoklonalne w leczeniu pacjentów z szpiczakiem mnogim (MM); teprotumumab do leczenia choroby oka tarczycy; Ofatumurnab, ludzkie przeciwciało monoklonalne w leczeniu przewlekłej białaczki limfocytowej (CLL) i stwardnienia rozsianego; oraz amivantamab dla zaawansowanego lub przerzutowego raka żołądka lub przełyku oraz NSCLC. Jego produkty obejmują daratumumab w leczeniu MM, nowotworów krwi nie-MM i amyloidozę Al; Gen1047; tisotumab vedotyna do leczenia nowotworów szyjnych, jajników i stałych; DUOBODY-PD-L1X4-1BB i DUOBODY-CD40X4-1BB do leczenia guzów litych; Epcoritamab dla nawrotowego/opornego rozproszonego chłoniaka z komórek B i przewlekłej białaczki limfocytowej; oraz heksabody-cd38 i duohexabody-cd37 do leczenia nowotworów hematologicznych. Firma opracowuje również produkty, które są w fazie 2 obejmują Teclistamab dla kryzysów wazo-okolonowych; Kamidanlumab tesiryna w leczeniu chłoniaka Hodgkina i guzów litych; JNJ-64007957 i JNJ-64407564 w celu leczenia MM; PRV-015 w leczeniu celiakii; MIM8 do leczenia hemofilii A; i LU AF82422 do leczenia choroby atrofii wielu układów. Ponadto ma około 20 aktywnych programów przedklinicznych. Firma ma umowę o licencji komercyjnej i współpracy z SEAGEN Inc. w celu wspólnego rozwoju tisotumabu weedotyny. Ma również umowę o współpracy z CureVac AG w zakresie badań i rozwoju zróżnicowanych produktów przeciwciał opartych na mRNA; Abbvie za rozwój Epcoritamab; oraz współpraca z Biontech, Janssen, Novo Nordisk A/S, Blink Biomedical SAS i Bolt Biotherapeutics, Inc. Genmab A/S zostały założone w 1999 roku i ma siedzibę w Kopenhadze w Danii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 2 635
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 9.89694
Ilość akcji: Brak danych
Debiut giełdowy: 2009-06-01
WWW: https://www.genmab.com
CEO: Dr. Jan G.J. van de Winkel Ph.D.
Adres: Kalvebod Brygge 43
Siedziba: 1560 Copenhagen
ISIN: US3723032062
Wskaźniki finansowe
Kapitalizacja (USD) 14 672 564 745
Aktywa: 39 660 000 000
Cena: 23.86
Wskaźnik Altman Z-Score: 3.4
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 14.0
Ilość akcji w obrocie: 10%
Średni wolumen: 1 401 765
Ilość akcji 615 072 930
Wskaźniki finansowe
Przychody TTM 19 763 000 000
Zobowiązania: 7 738 000 000
Przedział 52 tyg.: 17.235 - 28.56
Piotroski F-Score: 5
Umiarkowany (średnia jakość finansowa)
EPS: 1.7
P/E branży: 26.1
Beta: 0.859
Raport okresowy: 2025-08-07
WWW: https://www.genmab.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Christopher Cozic Executive Vice President & Chief People Officer 785 570 1978
Dr. Martine J. van Vugt Ph.D. Executive Vice President & Chief Strategy Officer 698 285 1971
Ms. Birgitte Stephensen M.Sc. Executive Vice President & Chief Legal Officer 640 094 1961
Dr. Jan G.J. van de Winkel Ph.D. Co-Founder, President & Chief Executive Officer 2 909 520 1961
Dr. Mijke Zachariasse Ph.D. Senior Director, Head of Antibody Research Materials & Non-Independent Director 160 024 1974
Mr. Martin Schultz Senior Director of Clinical Operations & Non-Independent Director 116 381 1976
Dr. Judith V. Klimovsky M.D. Executive Vice President & Chief Development Officer 1 178 356 1958
Mr. Anthony Mancini Executive Vice President & Chief Operating Officer 1 149 260 1971
Dr. Tahamtan Ahmadi Executive Vice President, Chief Medical Officer & Head of Experimental Medicines 1 120 165 1973
Mr. Anthony Pagano Executive Vice President & Chief Financial Officer 1 032 880 1978
Lista ETF z ekspozycją na akcje Genmab A/S
Symbol ETF Ilość akcji Wartość
IBB 2 501 173 51 324 063
EFA 2 160 929 44 342 261
FBT 1 666 541 34 197 421
EUNL.DE 984 152 20 194 789
IWDA.AS 984 152 20 194 789
SWDA.MI 984 152 20 194 789
IWLE.DE 984 152 20 194 789
IWDA.L 984 152 20 194 789
IWDD.AS 984 152 20 194 789
SWDA.L 984 152 20 194 789
IWDG.L 984 152 20 194 789
EFG 867 535 17 801 820
IXUS 802 231 16 461 784
2B78.DE 664 002 13 625 323
DRDR.L 664 002 13 625 323
HEAL.L 664 002 13 625 323
EUNK.DE 571 908 11 735 542
IMEA.SW 571 908 11 735 542
SMEA.L 571 908 11 735 542
IDEV 509 469 10 454 313
IQLT 497 222 10 202 993
IEUC.SW 493 870 10 134 213
IMEU.AS 493 870 10 134 213
IMEU.L 493 870 10 134 213
ISEU.L 493 870 10 134 213
IQQY.DE 493 870 10 134 213
ESGD 462 859 9 497 872
IEFA 409 608 83 354 497
EXIE.DE 405 520 8 321 275
EXSA.DE 405 520 8 321 275
IXJ 352 829 7 240 059
IEUR 307 756 6 315 160
EXV4.DE 269 909 5 538 525
AVDE 266 302 5 405 930
ESIH.L 261 004 5 355 805
ESIH.DE 261 004 5 355 805
WHCA.AS 238 661 4 897 327
CBUF.DE 238 661 4 897 327
WHCS.AS 238 661 4 897 327
SLMC.DE 233 595 4 793 373
SLMD.DE 233 595 4 793 373
SAEU.L 233 595 4 793 373
SDUE.L 233 595 4 793 373
FENI 232 753 4 757 471
ACWI 169 741 3 483 075
IUSQ.DE 167 202 3 430 978
ISAC.L 167 202 3 430 978
SSAC.L 167 202 3 430 978
VGK 150 232 31 692 877
EUMD.L 144 779 2 970 864
EMID.L 144 779 2 970 864
ACWX 139 751 2 867 696
CANC 130 217 2 643 405
AGES.L 127 646 2 619 300
2B77.DE 127 646 2 619 300
AGED.L 127 646 2 619 300
IEV 124 340 2 551 460
MVEU.L 96 695 1 984 172
IMVU.L 96 695 1 984 172
EUN0.DE 96 695 1 984 172
IMV.L 96 695 1 984 172
MVED.L 96 695 1 984 172
IQQU.DE 87 010 1 785 442
IEUX.L 87 010 1 785 442
EDM6.DE 78 631 1 613 510
EEUD.L 78 631 1 613 510
EMNU.DE 78 631 1 613 510
IVLU 70 114 1 438 732
FTQI 63 932 1 311 884
DMXF 53 106 1 089 732
S6DW.DE 52 631 1 079 982
SDWD.L 52 631 1 079 982
SNAW.DE 52 631 1 079 982
SAWD.L 52 631 1 079 982
URTH 44 379 910 654
FENI 40 457 8 293 555
CNCR 35 793 917 781
IEQD.L 33 617 689 814
IEFQ.L 33 617 689 814
CEMQ.DE 33 617 689 814
EDEN 33 532 6 823 702
IWDE.L 33 396 685 289
IBCH.DE 33 396 685 289
VWCE.DE 30 278 5 414 029
VGWL.DE 30 278 5 414 029
VWRL.L 30 278 4 676 966
VWRD.L 30 278 6 356 732
VWRL.AS 30 278 5 414 029
VWRP.L 30 278 4 676 966
SDG 29 930 614 157
VGEU.DE 29 262 5 411 519
VEUR.AS 29 262 5 411 519
VWCG.DE 29 262 5 411 519
VWCG.L 29 262 6 352 258
VEUD.L 29 262 6 352 258
VEUA.L 29 262 4 673 659
VEUR.L 29 262 4 673 659
VERX.DE 27 370 5 061 625
VERX.L 27 370 4 371 473
VERE.DE 27 370 5 061 625
VERG.L 27 370 4 371 473
VERE.L 27 370 5 941 538
VERX.AS 27 370 5 061 625
XEF.TO 25 831 7 252 894
2B70.DE 25 256 518 259
BTEC.L 25 256 518 259
BTEK.L 25 256 518 259
BTEE.L 25 256 518 259
IDNA 19 372 3 942 167
IWFS.L 19 178 393 540
IWSZ.L 19 178 393 540
IS3T.DE 19 178 393 540
AVIV 17 483 354 904
GSIE 15 409 3 135 704
EGMW.L 12 256 251 497
EEWG.L 12 256 251 497
EDMW.DE 12 256 251 497
EMND.DE 12 256 251 497
EEWD.L 12 256 251 497
VIU.TO 12 187 3 517 956
LCTD 12 059 247 453
IWDC.SW 10 423 213 889
EUXS.L 9 943 204 030
DFIV 9 780 198 534
IXJ.AX 8 034 2 538 081
VGVF.DE 6 413 1 146 712
VHVE.L 6 413 1 346 381
VGVE.DE 6 413 1 146 712
VDEV.L 6 413 1 346 381
VEVE.L 6 413 990 599
EXSC.DE 6 318 129 644
CEMT.DE 5 232 107 370
IEFS.L 5 232 107 370
MVEE.DE 5 105 104 759
MVEE.L 5 105 104 759
MVLD.AS 5 105 104 759
MVEE.SW 5 105 104 759
XEQT.TO 4 382 1 230 323
XFH.TO 3 759 1 055 525
XIN.TO 3 560 1 041 158
XHC.TO 3 257 914 427
IEU.AX 3 186 1 006 607
IGWD.L 3 046 62 501
AVSD 2 893 58 727
BMED 2 886 59 217
WPAB.SW 2 547 52 267
WPAD.AS 2 547 52 267
WPAB.AS 2 547 52 267
EPAD.AS 2 264 46 463
EUPB.AS 2 264 46 463
JHMD 2 166 425 898
WDNA.L 2 113 43 823
WBIO.L 2 113 43 823
TOK 2 073 42 531
XEU.TO 1 771 497 265
IBBQ 1 726 35 037
WINC.L 1 708 35 049
BIB 1 545 31 363
XAW.TO 1 463 410 846
IWLD.AX 1 325 418 580
IVE.AX 1 291 407 683
VE.TO 1 223 353 036
XDSR.TO 1 207 338 904
WDNA 967 22 066
V3AA.L 942 197 768
V3AL.L 942 197 768
XSEA.TO 941 264 216
XEH.TO 791 222 155
XWD.TO 752 219 919
IHWL.AX 750 236 932
TLTD 651 140 194
GSEU 631 128 407
GEQT.TO 184 51 603
GGRO.TO 157 43 989
GBAL.TO 97 27 271
DMCY 31 6 308
GCNS.TO 20 5 538
Wiadomości dla Genmab A/S
Tytuł Treść Źródło Aktualizacja Link
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. globenewswire.com 2025-02-25 16:30:00 Czytaj oryginał (ang.)
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference Media Release COPENHAGEN, Denmark; February 19, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its C hief F inancial O fficer Anthony Pagano and C hief D evelopment O fficer Judith Klimovsky will participate in a fireside chat at the 4 5 th Annual TD Cowen Health Care Conference in Boston , Massachusetts at 1 : 50 PM EST ( 7: 5 0 PM CET ) on March 3 , 202 5 . A webcast of the fireside chat will be available on Genmab's website at https://ir.genmab.com/events-presentations. globenewswire.com 2025-02-19 11:14:00 Czytaj oryginał (ang.)
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon Genmab reported strong Q4 2024 results, with $897.4 million in revenue, beating expectations and showing 29% Y/Y growth, driven by Darzalex royalties. 2025 revenue guidance was slightly ahead of consensus and expense guidance was surprisingly low, indicating only 7% growth, and enhancing the company's financial outlook. J&J's decision on GEN3014 is pending; I expect J&J to opt out, but remain bullish on Genmab's product portfolio, pipeline, and growth prospects. seekingalpha.com 2025-02-18 04:25:53 Czytaj oryginał (ang.)
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript Genmab A/S (GMAB) Q4 2024 Earnings Conference Call February 12, 2025 12:00 PM ET Company Participants Jan van de Winkel - CEO Brad Bailey - EVP and Chief Commercial Officer Anthony Pagano - CFO Tahamtan Ahmadi - Chief Medical Officer Judith Klimovsky - Chief Development Officer Conference Call Participants Jonathan Chang - Leerink Partners Paul Jeng - Guggenheim Securities, LLC Asthika Goonewardene - Truist Securities Yifeng Liu - HSBC Xian Deng - UBS Yaron Werber - TD Securities Matthew Phipps - William Blair Qize Ding - Redburn Atlantic Justin Smith - Bernstein Vikram Purohit - Morgan Stanley Rajan Sharma - Goldman Sachs Operator Hello, and welcome to the Genmab Full Year 2024 Financial Results Conference Call. As a reminder, this conference call is being recorded. seekingalpha.com 2025-02-14 11:32:11 Czytaj oryginał (ang.)
Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on Wednesday, March 12, 2025, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark.   The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, and Appendix 2: Proposed amended Remuneration Policy is attached. globenewswire.com 2025-02-13 08:00:00 Czytaj oryginał (ang.)
Genmab Files Annual Report with the U.S. Securities and Exchange Commission Media Release COPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2024. Both reports are available via the SEC's website, www.sec.gov and Genmab's website, www.genmab.com. globenewswire.com 2025-02-12 15:14:00 Czytaj oryginał (ang.)
Genmab Publishes 2024 Annual Report Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. globenewswire.com 2025-02-12 13:01:00 Czytaj oryginał (ang.)
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 4,903 restricted stock units and 5,289 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. globenewswire.com 2025-01-23 17:08:00 Czytaj oryginał (ang.)
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024 Company Announcement Net sales of DARZALEX ® in 2024 totaled USD 11,670 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 11,670 million in 2024. Net trade sales were USD 6,588 million in the U.S. and USD 5,082 million in the rest of the world. globenewswire.com 2025-01-22 08:23:00 Czytaj oryginał (ang.)
GMAB vs. QGEN: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Genmab A/S Sponsored ADR (GMAB) and Qiagen (QGEN). But which of these two stocks is more attractive to value investors? zacks.com 2025-01-16 14:41:12 Czytaj oryginał (ang.)
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2025-01-14 15:00:32 Czytaj oryginał (ang.)
Are Investors Undervaluing Genmab (GMAB) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-01-14 12:46:23 Czytaj oryginał (ang.)
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference Media Release COPENHAGEN, Denmark; January 03, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 4 3 rd Annual J.P. Morgan Healthcare Conference in San Francisco at 3:00 PM PST / 6:00 PM EST on January 1 4 , 202 5 , 12 :00 AM CET on January 15, 2025 . The live and archived webcast of the presentation will be available on Genmab's website at https://ir.genmab.com/events-presentations. globenewswire.com 2025-01-03 15:56:00 Czytaj oryginał (ang.)
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH Data Review Meeting today, December 11, 2024 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast. globenewswire.com 2024-12-11 10:20:00 Czytaj oryginał (ang.)
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL). Results from Arm 1 of the Phase 1b/2 EPCORE® NHL-2 trial (NCT04663347), evaluating fixed-duration epcoritamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), d. businesswire.com 2024-12-09 14:00:00 Czytaj oryginał (ang.)
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following. businesswire.com 2024-12-08 13:00:00 Czytaj oryginał (ang.)
Genmab Is Too Attractive To Ignore Genmab's shares are down to very attractive levels and hard to ignore. The company's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak, driven primarily by Darzalex and Kesimpta. Despite some setbacks and market concerns, Genmab's long-term growth prospects remain strong, supported by growing Epkinly revenues, expanding clinical pipeline and the acquisition of ProfoundBio. seekingalpha.com 2024-12-08 10:12:09 Czytaj oryginał (ang.)
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R2) Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent Results f. businesswire.com 2024-12-07 21:00:00 Czytaj oryginał (ang.)
Scancell strikes deal worth up to $630m with Genmab Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish biotech exclusive global rights to develop and commercialise a monoclonal antibody from the UK drug developer's GlyMab platform. proactiveinvestors.co.uk 2024-12-04 05:04:54 Czytaj oryginał (ang.)
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. globenewswire.com 2024-12-03 18:35:00 Czytaj oryginał (ang.)